The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
|Articles|October 1, 2010
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-10-01-2010
- Volume 22
- Issue 10
Quantitative open-access HPLC analysis: a new calibration approach
A novel tool enables users to generate reliable data for yields in solution and for assays of isolated solids using high?performance liquid chromatography without having to prepare standards.
Advertisement
A novel tool enables users to generate reliable data for yields in solution and for assays of isolated solids using high‑performance liquid chromatography without having to prepare standards. The authors discuss the approach taken to develop the tool, its associated protocols and how it can be used to calculate data.
Articles in this issue
about 16 years ago
Validating Single-Use Systemsabout 16 years ago
EGA Position On The EC's Proposal For A Falisifed Medicines Directiveabout 16 years ago
Green is the wordabout 16 years ago
Newsabout 16 years ago
The Pros And Cons Of Single-Use Systemsabout 16 years ago
Europe: A Future Leader in Vaccines?about 16 years ago
Developing A Quality Agreement Template For Single-Use Systemsabout 16 years ago
Online Monitoring Of Continuous Hot Melt Extrusionabout 16 years ago
An All-Round Excipient For Direct CompressionAdvertisement
Related to this article
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
4
France Remains One of Europe’s Leading Biotech Funding Hubs
5